FREDERICK W DRISCOLL
CIK 1129890 · Chief Financial Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.5K
Companies
11
Total Filings
67
Lifetime Open-Market Net
-$1.30M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CLRB | Director | 65 | $2.50 | $162 | $20.2K | 7 | 2026-07-08 |
| LITS | Director | — | $0.97 | — | $0 | 1 | 2025-11-18 |
| Lite Strategy, Inc. (MEIP) Delisted | Director | 1,875 | $3.20 | $6.0K | -$625 | 10 | 2025-07-17 |
| CUE | Director | — | $30.25 | — | $0 | 8 | 2025-01-03 |
| Renovacor, Inc. (RCOR.WS) Delisted | Chief Financial Officer | — | $0.07 | — | $0 | 1 | 2022-03-28 |
| FLXN | Chief Financial Officer | 0 | $24.65 | $0 | -$689.0K | 14 | 2021-11-19 |
| ImmunityBio, Inc. (NK) Delisted | Director | 124,535 | — | — | -$668.1K | 5 | 2020-08-13 |
| Cellectar Biosciences, Inc. (CLRBZ) Delisted | Director | — | $0.12 | — | $0 | 4 | 2020-06-25 |
| Oncotelic Therapeutics, Inc. (OXGN) Delisted | Director | — | — | — | $0 | 4 | 2016-06-03 |
| NVAX | VP, CFO & Treasurer | 1,000 | $7.37 | $7.4K | $23.6K | 7 | 2013-03-06 |
| GENELABS TECHNOLOGIES INC /CA (GNLB) Delisted | CEO | 0 | — | — | $10.0K | 6 | 2009-01-07 |
Recent Filings · Page 3 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-06 | CUE | Grant (A) | — | $0 | EDGAR |
| 2020-08-13 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −65,300 | -$668.1K | EDGAR |
| 2020-07-07 | Lite Strategy, Inc. (MEIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-25 | Cellectar Biosciences, Inc. (CLRBZ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | ImmunityBio, Inc. (NK) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-06 | CUE | Grant (A) | — | $0 | EDGAR |
| 2019-12-20 | Lite Strategy, Inc. (MEIP) Delisted | Buy (P) | +62,500 | $100.0K | EDGAR |
| 2019-07-03 | Lite Strategy, Inc. (MEIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-14 | Cellectar Biosciences, Inc. (CLRBZ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-07 | ImmunityBio, Inc. (NK) Delisted | Grant (A) | +92,592 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.